Replies

You'll have to read the article in detail. But it says under the section STUDY DESIGN

This study was a randomized, double-blind, placebo controlled trial, conducted at the Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, from September 2021 to November 2021.

The patients were randomized in a permuted block of four in a randomized sequence prepared by a pharmacist, who was unblinded, in Microsoft excel [28]. Allocation assignment was concealed from the investigators and patients. The patients were allocated in one of the two groups: group A (Ivermectin arm) or group B (control arm), as shown in Figure 1. The patients were randomized in a 1:1 ratio. Group A received 12 mg per day of ivermectin for 5 days, as recommended by previous studies [23, 25], along with standard care. Group B received standard care alone, which included favipiravir or andrographolide, corticosteroids, cetrizine and paracetamol.